<SUBMISSION>
<ACCESSION-NUMBER>0000950123-09-036968
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20090814
<ITEMS>5.02
<ITEMS>9.01
<FILING-DATE>20090820
<DATE-OF-FILING-DATE-CHANGE>20090820
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>RXI PHARMACEUTICALS CORP
<CIK>0001390478
<ASSIGNED-SIC>2834
<IRS-NUMBER>000000000
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>001-33958
<FILM-NUMBER>091027134
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>60 PRESCOTT  STREET
<CITY>WORCESTER
<STATE>MA
<ZIP>01605
<PHONE>508-767-3861
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>60 PRESCOTT  STREET
<CITY>WORCESTER
<STATE>MA
<ZIP>01605
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>b76917e8vk.htm
<DESCRIPTION>RXI PHARMACEUTICALS CORPORATION FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>WASHINGTON, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT<BR>
PURSUANT TO SECTION 13 OR 15(D) OF THE<BR>
THE SECURITIES EXCHANGE ACT OF 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Date of report (Date of earliest event reported): August&nbsp;14, 2009</B></DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B><FONT style="border-bottom: 1px solid #000000">RXI PHARMACEUTICALS CORPORATION</FONT></B>
</DIV>

<DIV align="center" style="font-size: 10pt">(Exact name of registrant as specified in its charter)</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">Delaware
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">001-33958
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">20-8099512</TD>
</TR>
<TR style="font-size: 1px">
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(State or other jurisdiction of <BR>
of incorporation or organization)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Commission<BR>
File Number)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(I.R.S. Employer<BR>
Identification No.)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>60 Prescott Street, Worcester, MA 01605</B><BR>
<DIV style="margin-top: 1px"><FONT style="border-top: 1px solid #000000">(Address of Principal Executive Offices) (Zip Code)</FONT></DIV></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">Registrant&#146;s telephone number, including area code: <B>(508)&nbsp;767-3861</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Not Applicable</B><BR>
Former name or former address, if changed since last report</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (<I>see </I>General Instruction A.2. below):
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Written communications pursuant to Rule&nbsp;425 under the Securities Act
(17 CFR 230.425)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act
(17 CFR 240.14a-12)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))</TD>
</TR>

</TABLE>
</DIV>

<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>


<DIV style="font-family: 'Times New Roman',Times,serif">

<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD colspan="9"><A HREF="#000">Item&nbsp;5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers</A></TD></TR>
<TR><TD colspan="9"><A HREF="#001">Item&nbsp;9.01&nbsp;&nbsp;Financial Statements and Exhibits</A></TD></TR>
<TR><TD colspan="9"><A HREF="#002">Signature</A></TD></TR>
<TR><TD colspan="9"><A HREF="#003">Index to Exhibits</A></TD></TR>
<TR><TD colspan="9"><A HREF="b76917exv99w1.htm">EX-99.1 Press Release issued by RXi Pharmaceuticals Corporation on August 20, 2009.</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>






<!-- link1 "Item&nbsp;5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers" -->
<DIV align="left"><A NAME="000"></A></DIV>
<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;5.02</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.</B></TD>
</TR>
</TABLE>
</DIV>





<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(b)&nbsp;On August&nbsp;14, 2009, Stephen DiPalma,  Executive Vice President of
Business Operations and Chief Financial Officer of RXi Pharmaceuticals Corporation (the &#147;Company&#148; or &#147;RXi&#148;), informed the
Company that he is resigning from RXi, effective August&nbsp;28, 2009 to pursue other opportunities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">A copy of the press release issued in connection
with Mr. DiPalma&#146;s resignation is being filed as
Exhibit 99.1 to this report and is incorporated herein by
reference.</div>



<!-- link1 "Item&nbsp;9.01&nbsp;&nbsp;Financial Statements and Exhibits" -->
<DIV align="left"><A NAME="001"></A></DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;9.01</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Financial Statements and Exhibits.</B></TD>
</TR>
</TABLE>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibits.</div>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99.1
Press Release issued by RXi Pharmaceuticals Corporation on August 20,
2009.</div>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<!-- link1 "Signature" -->
<DIV align="left"><A NAME="002"></A></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Signature</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="14%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">RXI PHARMACEUTICALS CORPORATION</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Date:
August&nbsp;20, 2009
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Tod Woolf
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tod Woolf</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chief Executive Officer</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">






<!-- link1 "Index to Exhibits" -->
<DIV align="left"><A NAME="003"></A></DIV>
<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">

    <TD colspan="3" align="center"><b>Index to Exhibits</b></TD>
</TR>
<TR style="font-size: 10pt">
<td>&nbsp;</td>
</TR>

<TR valign="top">
    <TD nowrap align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>99.1 Press Release issued by RXi Pharmaceuticals Corporation on August 20, 2009.</TD>
</TR>
</TABLE>
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>b76917exv99w1.htm
<DESCRIPTION>EX-99.1 PRESS RELEASE ISSUED BY RXI PHARMACEUTICALS CORPORATION ON AUGUST 20, 2009.
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt">Exhibit 99.1</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><IMG src="b76917b7691700.gif" alt="(RXI LOGO)">
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>RXi Pharmaceuticals Announces Departure of Chief Financial Officer</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Worcester, MA, August&nbsp;20, 2009 &#150; </B>RXi Pharmaceuticals Corporation (Nasdaq: RXII) today announced
that Stephen J. DiPalma, has resigned as Executive Vice President of Business Operations and Chief
Financial Officer to pursue other opportunities, effective August&nbsp;28, 2009.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Tod Woolf, Ph.D. President and CEO said, &#147;We would like to thank Steve for his leadership and
important contributions as RXi expanded its operations, became a public company in early 2008 and
closed subsequent rounds of financing. We wish Steve well in his
future endeavors. &#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Company will be recruiting a new Chief Financial Officer.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>About RXi Pharmaceuticals Corporation</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">RXi Pharmaceuticals is a discovery-stage biopharmaceutical company pursuing the development and
potential commercialization of proprietary therapeutics based on RNA interference (RNAi) for the
treatment of human diseases. RXi has a comprehensive therapeutic platform that includes both RNAi
compounds and delivery methods. RXi uses its own version of RNAi compounds &#151; rxRNA&#153; &#151; that
provide an advanced alternative to conventional small interfering RNAs (siRNAs) and define the next
generation of RNAi technology. rxRNA&#153; compounds are designed specifically for therapeutic use and
contain many of the properties needed to move RNAi based drugs into the clinic. RXi
Pharmaceuticals believes it is well positioned to compete successfully in the RNAi-based
therapeutics market with its accomplished scientific advisors, including Dr.&nbsp;Craig Mello, recipient
of the 2006 Nobel Prize for his co-discovery of RNAi; a management team that is experienced in
developing RNAi products; and a strong early intellectual property position in RNAi chemistry and
delivery. <u>www.rxipharma.com</u>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Forward-Looking Statements</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This press release contains forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about
future expectations, plan and future development of RXi Pharmaceutical Corporation&#146;s products and
technologies. These forward-looking statements about future expectations, plans and prospects
regarding the ability of the company to attract and retain key employees, plans and prospects of
the development of RXi Pharmaceutical Corporation&#146;s products and technologies involve significant
risks, uncertainties and assumptions, including the risk that the development of our RNAi-based
therapeutics may be delayed or may not proceed as planned and we may not be able to complete
development of any RNAi-based product, the risk that the FDA approval process may be delayed for
any drugs that we develop, risks related to development and commercialization of products by our
competitors, risks related to our ability to control the timing and terms of collaborations with
third parties <I>and </I>the possibility that other companies or organizations may assert patent rights
that prevent us from developing our products. Actual results may differ materially from those RXi
Pharmaceuticals Corporation contemplated by these forward-looking statements. RXi Pharmaceuticals
Corporation does not undertake to update any of these forward-looking statements to reflect a
change in its views or events or circumstances that occur after the date of this release.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>CONTACT:</B><BR>
RXi Pharmaceuticals<BR>
Donna Falcetti<BR>
508-929-3615<BR>
ir@rxipharma.com

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">or

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Investors<BR>
SAN Group<BR>
Susan Noonan<BR>
212-966-3650<BR>
susan@sanoonan.com

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">or

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Media<BR>
Rx Communications Group<BR>
Eric Goldman<BR>
917-322-2563<BR>
<u>egoldman@rxir.com</u>

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>b76917b7691700.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 b76917b7691700.gif
M1TE&.#EA/`!&`.8``,J)OF$`:78S=_[^_5$$5K2OJ'=(<,N5P8%6?/CL\STY
M++5WL5P`8^3(XI1FCIJ3BHL[AJF6G?W]^KM_K\6IOMK%U.7/X*9EH_K]]7T[
M>CXW,8!&@/WU^3PS+D`U,+"?IET`:-N_U)=:E/WX^_SP]O/:Z]*BREI02N[5
MY\:BP/;D\.KHXO[Z_$`X+:)SG+&$K6E<6;R(MJIXI<&^LZF'I64`;]W9U7MR
M;/'XZ*:AF'$U;_K]^6HM:)U2F9](F6XW;'\L?^7?W=>ISV(49TY$/M*TS>6Z
MV4$Y,LBVO<![LHQ5B5P58LO$P:=<HFYI7T4[.XB!>58!7\"4N:]MIT4T.-C3
MS_S\_-/+RY%)C;*:I4LY._;U\/OY^/#-Y6P6;V(+8GH:>Z)JI?;\[UDL5V\"
M=#HO*UH)8#HZ*)10CF`*;60C94@V,U8,7(M"A[=IL%\`;EUC2S<Y*#HU+#D[
M*D8_-4HX/5H<7FXB<?C\^F]`:I]=FN_PZ5D)9E@`9E$V/D$V,B'Y!```````
M+``````\`$8```?_@$`"@SJ%AH.(B8J+`H>-A8R1.CR3&2A``)F:FYR=GIDF
M)D*B)E('IZBIJJ>F)CP6;0"%E(Z1CX:X.C]2+"-6+`4PPL/$Q<5(>15M200$
M4<_0?=+3U%$,UPS0U@0;)2,#`P5R+2UGYN?HZ7%/'WD-$`O/;V\U]37S^/EO
M`0$U_/_]R`PYP$*"A"M:UGB@PK"APS,*6FA0H(%*%AWOF$7I`R(?B(\@0UX#
MR(<,"`9D&.@9@6&`C1,>6OR92;/F'`4XYYQA]Z/!,F<,``H=RO$?""]@^)&)
M(H`#N"`P.DS$2;6JAJESYCRYZ)/92'XGAP(LRB\*$"`@^C%8HF*`!*A4_Z96
MK4KESU6=6KBVF4!`VCP0TK`)Q@;M6A0?=ZP!)M!E`)X@3C3,N4JY<D6&4^MD
M$9`Q"C]_`:[9&VU/VK\T33@&94#@`(>W,-;(K$F[;@L%6=EAA,`,,(@::4'_
MOK<O])N@;T!D<-/16N@D+#"\;.&!]LP.?SQH..+!`VZ>[_@"[@,\"KU^^?@Q
M`![@31\'4S8^JQ'%3<$J1"1:[]!=^Y'L.($'`5^A,?!&%,UDPT!'\ZB77'M]
MO!!?'_-%T41!3-"A'VT='-%!!W)D]X<<"@A((#9#](#%BA!XT5=:`?R6UH$I
M7&">-?3U4%`!+<BA`6T>''$$'2><0$091]QF(O\!H876!@E.<4`""BX0L&!'
M[($010@VNO<;`SIBD(,<(7+H00</;(%##MT%^$%/`S*YV@8<L+!%$`F,0$(&
MYC6(7!0-A$%`#7VL!R8+.T#1XX\U\8>F03F4\8>;<!*HW@;?(&%`"M],P8<T
M:?V)@@P$N&?HA7LXT6-U0*(9A`T/='=$B6^&QZ2,F`Z0@AUA./4"'\F%VEX4
M*DA!`&!1T&=?%2<L:MT?'1!1)!%!*EEKG!\!E^L!2UQ``@8OI'%@C$$%0*P0
M2\R3;!0``*/A;$">&61UM]%:Z;&_O='&:[N&P04.OQ9*;EDE-"#`/:N9P`(4
M26Y(DZQE@%C=K/;:^E'_<KFFL$08$HCQZWE!U1.%#0DXD&T`C$D`1XC>6;:=
M!C?,,`,4'=RFU0>[B1<4"!NPH.L0843W<0WEUM,'$AP(<2RA;*U`1X@=4.3R
MHSOD\(?-NEF\<\\#4`#T"#O\*NQP(&0Q@@HZK,L#"3/$H<&94E,F%9H85/WA
M=SAK'2/77E\`]J^AW=H/""Z0,(();&B)1@)0S,&==BYK(,<#;K&)==[8;NUS
M"D/X';8990$'8P8E#)"`$@C*$,0)"LAQA`92628'U3G4W,+-.1^K^<]3<.&Q
M&46'5<,71=19@A=VI,#$K)1!+OL#D,:$=^YA\;SYQBR]`#IPR2U(7^$#C#!%
M_S<T5V979:]/'OWEU.].@1TRL,"%'E'`"%9'(`A0`@LL3."""D20"DY^9)GT
M04\"EIN>WJPW@"J\P`(CL(`79-2D&/V&#S$8`0NPD((91$QZ%2F@Y`Z80-PM
MD&L8(($*LC`&L!1J/<`A3Q]T0(($M*$!#Z#6I"@2%_2-<'T*S-S>?+:%$B1@
M#T@80D!@-)ZTL&L!$:@"#)CU(7+4BS*O>Q0"I6="(3*0"4H00OAZ`$,FFL9<
M=U"##0K@A!',@#M6)`<684="+F;-BWSC54$F`*R/W(\C1./&"!Y`.18XH4-Q
MG*,62WA'G0U15QO;XZ>.DQ:0T(,!;!`"9)C@LQG`Y/],<KQ*%NO(OA/Z3`I?
M`Q<;/%,_L/@)""A`P@FN8`4N;(%FW0GERQ9I1\PYDH&<"UK8V+`:)C:(`$D@
M`13^<((5^(P)`6R8(DD9Q%]R+9@2`!?PP'(_+7D!!1PXP8?2-(`5W(!>$A$E
M'8'816M>CV/:+!<3G8@&$@3A.G1@@@2X4(`JIG.7U&RG[AZIL:!I$W]F9,`0
M3$""2/VA#!Z``1<D8(,G7.V?HV1G(P<*S$A*0'L=Z8-1*$2Z+3A!`=CY$!.L
M8`5QZC*C6RQEG$;"LV]08&.^FT`:*'2E?M2``#3@P@J:18[NW&`%$J#9LW@I
M4[Z,A`&8D@#G+L`!,>BT>L'_><,0BL"%*KQK-D309P&>!:V`;K1)4"W(5*L:
M+C_Z,4:6X,(;K7B=!W#A"A;=CUE]R:1+J;5S)/!8&C[#Q"C((`$+BP@Y9N(!
M)^RAHDO=*T;VTM?0\*U;@=7>9XJ3C2*,0`).&,=B_W"$L`:!")'5*%__T0<Z
M<4!C]<2`QHS#D9-\004CV`(11`NO(^1@!:C=3PXJ=S>!6A`$$"A!";B5W`28
MP`N*$:FY,D`"%JS@"+RE20>@,%0@E74/>XB43)D1`(YHM0=H@,`74N2`-NST
M(YY!V11\9@/)T?4Z,``NA[(#`RA``0;C"")YI>$/:ZSG)/*8!Z%"PP:%#8`)
M4;OO_TQ.<%K:<(>T99A=DH[0Q0'WP4L!L4=[%"Q23(8`'!Y4++P\0`3(UJ0[
MC-U.DN1@PF74CQ[)H9!86!L:-5A@`#L01QSC2(09?'7(MU$(@!20EY[\9$%_
M"<N.RQN:.Y0.`_WL3W\^=(('4$?+8,[.57"BF<EZI2/WFW*,S`4$%63S`_R)
MUPF<P"JR4H8J9>X*4`!BOQT?Z$D8P'*<@42$X)+U?#B!2)Z?C)Q[J!D]4<#"
MM[#<'9?)@0Z1L\Q-$LUDKL`#*`LR2DA&7>`><``#$O"@\S+-ZJO$,2\\R(@S
MGO'";&CCUJ&)@AY((`$6,($*:W"(L(<M["<P9`W(]D/>VO\@A`4X^]G0CK:T
M&3H"#@0A`MC.MK:WS6UN9R$"%<A``]0PB`UDX-SH3K>Z,V"`#;0A`WDP0![B
M'6\#V/O>^,ZWOO.=AS$TH`(A"$$%!D[P@AM\X%4P>,"+$/"&._SA$!>XPP<>
M`B.0``\LW0$X?%:G0///%QMWR@Y^X92-:QP<*$^YSUC*`BN@O.4^2SE+'8.'
M0+?$+=ELB01<OH.1#\!G=?LYRCN6\J*[90`L;[G+#2*!HALD?%R8*`:X`(YL
MLG3F5N@YTG<0="`WG>A&'[K&J\T_*^`AFT__N16R.0`5J"`!'%!!W!.@@BW@
M085PESO64>WRF:,][%67P`CT5$/_$DC=("RHH09;H@8=Y$$(>3""`UZ`@`I8
M@09CR$,,E%"\7M1I\!RH-ME9P('0EYY_I:\V"4@@A130@`:E[[644(``%!C>
M"EX`0`:2(`(!9,`(4VC``,*@A!@@10D.0`$-')""%+A`"BZ(O@QD$`(7)#\&
M#BA"$29/@10T0`8ZV,`$I"`%!U!@^RX00@8.X``9K.`+/1"`$(Q``#V40`=<
MO4`&1``!,%S@!P<@`FB`!4JP`0=P!R)@!PLP!"^@?VYP!]:W`1>@!DH@`JZ`
M!2*`7CSP`@ZP`%-P!TD@`&VP`7I@`5^@!SH@!$JC!"C``YXU!3Q``T8`!@>P
M`0#0!!D`U@%8``!=(`!2H`8-X`4QT`-WX`-`4`*NX`,0@`8B<``ZT`0N<`$0
MH`9=8`0`T`-#L`!`X`9`@`4H,`1"4'P_H'\'8`=%P`)AX``U=`<I@`!&.`40
ML`$Q8#!28`<-,`0\,`58X`-@$`-M(``'T`-ZT`8+H`,7(`)-T`9J8`(0<`=3
ML(5`T`0`,`04X`-&T(`;T`7.U@0G%@,T8`4<(`)%(`,'``0B<`'IIP(7$(9=
KT`,RD`$]<(,Z(`4FH`9-H'Y8L(H9H`<3`(,QL``"$(L7,`$\@`4E$`@`.S\_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
